About this research peptide
Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) under active investigation in published preclinical and early-stage clinical research. Investigators studying metabolic-endocrine dysregulation in women have referenced Retatrutide for its multi-pathway pharmacology.
Researchers exploring conditions that disproportionately affect women — including autoimmune-driven inflammation, perimenopausal symptom mapping, hormonal-metabolic dysregulation, and post-surgical recovery in women’s-health procedures — have included this compound in their reference libraries.
This product is supplied as a lyophilized powder of ≥99% purity, with a lot-specific Certificate of Analysis available through the link in the Specifications tab.
Cited research
Cited research will be published on this product page as new literature is indexed. Citations are provided for research context only — inclusion does not imply any health claim or endorsement of personal use.









